Related Experiment Videos
BGP (osteocalcin, bone-Gla-protein) in involutional osteoporosis.
A Rapado1, C de la Piedra, R Torres
1Unidad Metabólica, Fundación Jimenez Diaz, Madrid, Spain.
Clinical Rheumatology
|June 1, 1989
Summary
Lower levels of bone gamma-carboxyglutamate protein (BGP), also known as osteocalcin, were found in osteoporosis patients. This bone marker showed correlation with alkaline phosphatase but not other tested markers.
Area of Science:
- Endocrinology
- Orthopedics
- Biochemistry
Background:
- Involutional osteoporosis management relies on accurate bone markers.
- Bone gamma-carboxyglutamate protein (BGP), or osteocalcin, is a potential marker.
- Radioimmunoassay methods for BGP have limitations.
Purpose of the Study:
- To evaluate the role of serum BGP (osteocalcin) as a bone marker in involutional osteoporosis.
- To assess the correlation of sBGP with other established bone turnover markers and bone mineral content.
Main Methods:
- Radioimmunoassay was used to measure serum BGP (sBGP) levels.
- Comparison of sBGP levels between osteoporotic patients and a control group.
- Correlation analysis between sBGP and serum alkaline phosphatase, urinary hydroxyproline/creatinine ratio, serum tartrate-resistant acid phosphatase, and bone mineral content.
Main Results:
- Significantly lower sBGP levels were observed in osteoporotic patients compared to controls.
- A positive linear correlation was found between sBGP and serum alkaline phosphatase.
- No significant correlation was found between sBGP and urinary hydroxyproline/creatinine ratio, serum tartrate-resistant acid phosphatase, or bone mineral content.
Conclusions:
- Serum BGP (osteocalcin) may serve as a valuable marker in the study and management of involutional osteoporosis.
- sBGP's correlation with alkaline phosphatase suggests a link to bone formation, but its utility alongside other markers requires further investigation.